© 2004 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Delayed preconditioning of the human myocardium: signal transduction and clinical implications
Department of Integrative Human Cardiovascular Physiology and Cardiac Surgery, University of Leicester, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK
* Corresponding author. Tel.: +44-116-2563032; fax: +44-116-2502449. mg50{at}le.ac.uk
Objective: Ischemic preconditioning confers cardioprotection in early and delayed phases. We investigated the delayed window of pharmacological and ischemic preconditioning in human myocardium, and the involvement of mitoKATP, PKC and p38MAPK. Methods: These studies were carried out using human right atrial tissue in a cell necrosis model. The tissue was obtained from patients undergoing coronary artery surgery. Results: The second window triggered by ischemia, phenylephrine or adenosine resulted in similar cardioprotection between 24 and 72 h following the intervention. Atrial tissue taken from patients with a single episode of angina between 24 and 72 h prior to surgery were already protected and preconditioning with ischemia, phenylephrine or adenosine did not add to the protection. The trigger of preconditioning with mitoKATP channel opener diazoxide, PKC activator PMA and p38MAPK activator anisomycin produced similar delayed protection to that of ischemia or phenylephrine. Cardioprotection was lost when mitoKATP channels were blocked by 5HD, PKC by chelerythrine and p38MAPK by SB203580 24 h after the trigger of preconditioning. Conclusions: Ischemic and pharmacological preconditioning induce similar delayed cardioprotection of the human heart. This second window of protection that is seen between 24 and 72 h occurs in vitro and in vivo and requires opening of mitoKATP channels and activation of PKC and p38MAPK.
KEYWORDS Delayed preconditioning; Human myocardium; Signal transduction
Time for primary review 00 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. Golomb, A. Nyska, and H. Schwalb Occult Cardiotoxicity--Toxic Effects on Cardiac Ischemic Tolerance Toxicol Pathol, August 1, 2009; 37(5): 572 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Gao, L. Chen, and H.-T. Yang Activation of {alpha}1B-adrenoceptors alleviates ischemia/reperfusion injury by limitation of mitochondrial Ca2+ overload in cardiomyocytes Cardiovasc Res, August 1, 2007; 75(3): 584 - 595. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial Membrane Permeabilization in Cell Death Physiol Rev, January 1, 2007; 87(1): 99 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Kudej, Y.-T. Shen, A. P. Peppas, C.-H. Huang, W. Chen, L. Yan, D. E. Vatner, and S. F. Vatner Obligatory Role of Cardiac Nerves and {alpha}1-Adrenergic Receptors for the Second Window of Ischemic Preconditioning in Conscious Pigs Circ. Res., November 24, 2006; 99(11): 1270 - 1276. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Martou, C. A. O'Blenes, N. Huang, S. E. McAllister, P. C. Neligan, H. Ashrafpour, C. Y. Pang, and J. E. Lipa Development of an in vitro model for study of the efficacy of ischemic preconditioning in human skeletal muscle against ischemia-reperfusion injury J Appl Physiol, November 1, 2006; 101(5): 1335 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Moses, P. D. Addison, P. C. Neligan, H. Ashrafpour, N. Huang, S. E. McAllister, J. E. Lipa, C. R. Forrest, and C. Y. Pang Inducing late phase of infarct protection in skeletal muscle by remote preconditioning: efficacy and mechanism Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1609 - R1617. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Gross, J. N. Peart, A. K. Hsu, J. A. Auchampach, and G. J. Gross Extending the cardioprotective window using a novel {delta}-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2744 - H2749. [Abstract] [Full Text] [PDF] |
||||







